1
|
Descamps A, Arnoux P, Frochot C, Barbault F, Deschamp J, Monteil M, Migianu-Griffoni E, Legigan T, Lecouvey M. Synthesis and preliminary anticancer evaluation of photo-responsive prodrugs of hydroxymethylene bisphosphonate alendronate. Eur J Med Chem 2024; 269:116307. [PMID: 38460269 DOI: 10.1016/j.ejmech.2024.116307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Revised: 03/01/2024] [Accepted: 03/04/2024] [Indexed: 03/11/2024]
Abstract
The antitumoral activity of hydroxymethylene bisphosphonates (HMBP) such as alendronate or zoledronate is hampered by their exceptional bone-binding properties and their short plasmatic half-life which preclude their accumulation in non-skeletal tumors. In this context, the use of lipophilic prodrugs represents a simple and straightforward strategy to enhance the biodistribution of bisphosphonates in these tissues. We describe in this article the synthesis of light-responsive prodrugs of HMBP alendronate. These prodrugs include lipophilic photo-removable nitroveratryl groups which partially mask the highly polar alendronate HMBP scaffold. Photo-responsive prodrugs of alendronate are stable in physiological conditions and display reduced toxicity compared to alendronate against MDA-MB-231 cancer cells. However, the antiproliferative effect of these prodrugs is efficiently restored after cleavage of their nitroveratryl groups upon exposure to UV light. In addition, substitution of alendronate with such photo-responsive substituents drastically reduces its bone-binding properties, thereby potentially improving its biodistribution in soft tissues after i.v. administration. The development of such lipophilic photo-responsive prodrugs is a promising approach to fully exploit the anticancer effect of HMBPs on non-skeletal tumors.
Collapse
Affiliation(s)
- Aurélie Descamps
- Université Sorbonne Paris Nord, Department of Chemistry, UMR-CNRS, 7244, 1 Rue de Chablis, F-93000, Bobigny, France
| | | | - Céline Frochot
- Université de Lorraine, CNRS, LRGP, F-54000, Nancy, France
| | | | - Julia Deschamp
- Université Sorbonne Paris Nord, Department of Chemistry, UMR-CNRS, 7244, 1 Rue de Chablis, F-93000, Bobigny, France
| | - Maelle Monteil
- Université Sorbonne Paris Nord, Department of Chemistry, UMR-CNRS, 7244, 1 Rue de Chablis, F-93000, Bobigny, France
| | - Evelyne Migianu-Griffoni
- Université Sorbonne Paris Nord, Department of Chemistry, UMR-CNRS, 7244, 1 Rue de Chablis, F-93000, Bobigny, France
| | - Thibaut Legigan
- Université Sorbonne Paris Nord, Department of Chemistry, UMR-CNRS, 7244, 1 Rue de Chablis, F-93000, Bobigny, France.
| | - Marc Lecouvey
- Université Sorbonne Paris Nord, Department of Chemistry, UMR-CNRS, 7244, 1 Rue de Chablis, F-93000, Bobigny, France.
| |
Collapse
|
2
|
Sánchez-Puetate JC, Silva BLG, Pinotti FE, Marcantonio CC, de Oliveira GJPL, Junior EM, Marcantonio RAC. Assessing bone formation on hydrophilic and hydrophobic implant surfaces in a murine model treated with bisphosphonates. Clin Oral Investig 2024; 28:89. [PMID: 38217802 DOI: 10.1007/s00784-023-05480-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Accepted: 12/27/2023] [Indexed: 01/15/2024]
Abstract
OBJECTIVE To evaluate the osseointegration of implants with hydrophobic (HFB) and hydrophilic (HFL) surfaces in a murine model of high-dose bisphosphonates (BPs). MATERIALS AND METHODS Sixty-four rats were randomly allocated into four groups: control group with HFB implants (CG-HFB), control group with HFL implants (CG-HFL), BP group with HFB implants (BP-HFB), and BP group with HFL implants (BP-HFL). Animals were euthanized after 15 and 45 days (n=8). The dependent variables assessed were the removal torque (biomechanical analysis), the bone volume around the implants (%BV/TV) (microtomographic analysis), the bone-implant contact (%BIC), the bone between the threads (%BBT) (histomorphometric analysis), and the expression of bone metabolism markers (immunohistochemistry analysis). RESULTS The CG-HFL and BP-HFL groups presented higher removal torque than the CG-HFB and BP-HFB implants. The %BIC of the CG-HFL surfaces was slightly higher than that of the CG-HFB implants. The BP-HFB and BP-HFL groups presented a higher %BIC than that of the CG-HFB and CG-HFL groups (p<0.001). BP therapy also increased the %BBT at both implant surfaces. Higher levels of ALP were observed in the matrix region of bone tissue on the HFL surfaces than on the HFB surfaces. CONCLUSION Both surfaces enable osseointegration in rats under BP therapy. CLINICAL RELEVANCE The study demonstrates that hydrophobic (HFB) and hydrophilic (HFL) implant surfaces can promote osseointegration in rats undergoing bisphosphonate therapy. The HFL surfaces exhibited improved biomechanical performance, higher bone-implant contact, and increased bone volume, suggesting their potential clinical relevance for implant success in individuals on bisphosphonate treatment.
Collapse
Affiliation(s)
- Julio Cesar Sánchez-Puetate
- Department of Diagnosis and Surgery, School of Dentistry of Araraquara, São Paulo State University (UNESP), Araraquara, Brazil
| | - Bruno Luís Graciliano Silva
- Department of Diagnosis and Surgery, School of Dentistry of Araraquara, São Paulo State University (UNESP), Araraquara, Brazil
| | - Felipe Eduardo Pinotti
- Department of Diagnosis and Surgery, School of Dentistry of Araraquara, São Paulo State University (UNESP), Araraquara, Brazil
| | - Camila Chierici Marcantonio
- Department of Diagnosis and Surgery, School of Dentistry of Araraquara, São Paulo State University (UNESP), Araraquara, Brazil
| | | | - Elcio Marcantonio Junior
- Department of Diagnosis and Surgery, School of Dentistry of Araraquara, São Paulo State University (UNESP), Araraquara, Brazil
| | | |
Collapse
|
3
|
Significance of bisphosphonates on angiogenesis in vivo and their effect under geranyl-geraniol addition - could it alter the treatment of bisphosphonate-associated necrosis of the jaw? Oral Maxillofac Surg 2022:10.1007/s10006-022-01053-2. [PMID: 35397019 DOI: 10.1007/s10006-022-01053-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2021] [Accepted: 03/03/2022] [Indexed: 10/18/2022]
Abstract
PURPOSE The aim of this study was to contribute to the understanding of the inhibitory effects of bisphosphonates on tissues, with a special focus on angiogenesis. Referring to bisphosphonate-associated osteonecrosis of the jaw (BP-ONJ), it should be shown that the local addition of the isoprenoid geranyl-geraniol (GGOH) prevents vascularization processes. METHODS A mouse model with n = 24 animals which received an injection of a collagen matrix was used. In 4 subgroups (n = 6), we examined the effect of zoledronate on the sprouting of capillary-like structures into the matrix, with and without the presence of geranyl-geraniol, as well as testing against control groups with PBS injections or collagen matrix containing PBS instead of GGOH. This was followed by a histological evaluation of the capillary-like structures. RESULTS Zoledronate inhibits the sprouting of blood vessels into a collagen matrix in vivo; in the presence of GGOH this effect is significantly weakened by a factor of 3.9 (p = 0.00068). CONCLUSION This work commits to the investigation of the pathophysiology of BP-ONJ and shows a possible causal therapeutic path via the topical application of GGOH.
Collapse
|
4
|
Baidya SK, Amin SA, Jha T. Outline of gelatinase inhibitors as anti-cancer agents: A patent mini-review for 2010-present. Eur J Med Chem 2020; 213:113044. [PMID: 33279289 DOI: 10.1016/j.ejmech.2020.113044] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Revised: 10/15/2020] [Accepted: 11/18/2020] [Indexed: 12/25/2022]
Abstract
Matrix metalloproteinases (MMPs) are involved in several pathological and physiological functions. Gelatinases (MMP-2 and -9) have significant attention as therapeutic targets against cancer. Gelatinase inhibitors have demonstrated their effectiveness in several diseases including cancer. However, it is quite a challenging task to develop inhibitors as a therapeutic agent. This review summarizes the patent dedicated to the medicinal chemistry of gelatinase inhibitor reported over last decades. We examine the patent being pursued for gelatinase inhibitor development to highlight the key issues. The main aim is to provide the scientific community with an overview of the patented gelatinase inhibitors to allow further development. During early 2000s, some MMP inhibitors failed to pass the clinical trials. Hence, the lessons learned from early evidence and recent knowledge in that field will rejuvenate the development of selective inhibitors. Various studies and patents have continued in the recent years to expand knowledge. Continuously, our research team has been involved in the design of potent and selective gelatinase inhibitors for the past few years. This study is a part of our efforts. This study may be beneficial in the design and development of better gelatinase inhibitors in the future.
Collapse
Affiliation(s)
- Sandip Kumar Baidya
- Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, P. O. Box 17020, Jadavpur University, Kolkata, 700032, West Bengal, India.
| | - Sk Abdul Amin
- Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, P. O. Box 17020, Jadavpur University, Kolkata, 700032, West Bengal, India.
| | - Tarun Jha
- Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, P. O. Box 17020, Jadavpur University, Kolkata, 700032, West Bengal, India.
| |
Collapse
|
5
|
Dussart J, Deschamp J, Migianu-Griffoni E, Lecouvey M. From Industrial Method to the Use of Silylated P(III) Reagents for the Synthesis of Relevant Phosphonylated Molecules. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.9b00490] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- Jade Dussart
- Université Sorbonne Paris Nord, CSPBAT, CNRS UMR 7244, UFR SMBH, 1 Rue de Chablis, F-93000 Bobigny, France
| | - Julia Deschamp
- Université Sorbonne Paris Nord, CSPBAT, CNRS UMR 7244, UFR SMBH, 1 Rue de Chablis, F-93000 Bobigny, France
| | - Evelyne Migianu-Griffoni
- Université Sorbonne Paris Nord, CSPBAT, CNRS UMR 7244, UFR SMBH, 1 Rue de Chablis, F-93000 Bobigny, France
| | - Marc Lecouvey
- Université Sorbonne Paris Nord, CSPBAT, CNRS UMR 7244, UFR SMBH, 1 Rue de Chablis, F-93000 Bobigny, France
| |
Collapse
|
6
|
Yalcin-Ulker GM, Cumbul A, Duygu-Capar G, Uslu Ü, Sencift K. Preventive Effect of Phosphodiesterase Inhibitor Pentoxifylline Against Medication-Related Osteonecrosis of the Jaw: An Animal Study. J Oral Maxillofac Surg 2017; 75:2354-2368. [PMID: 28529150 DOI: 10.1016/j.joms.2017.04.017] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2017] [Revised: 04/10/2017] [Accepted: 04/10/2017] [Indexed: 11/18/2022]
Abstract
PURPOSE The aim of this experimental study was to investigate the prophylactic effect of pentoxifylline (PTX) on medication-related osteonecrosis of the jaw (MRONJ). MATERIALS AND METHODS Female Sprague-Dawley rats (n = 33) received zoledronic acid (ZA) for 8 weeks to create an osteonecrosis model. The left mandibular second molars were extracted and the recovery period lasted 8 weeks before sacrifice. PTX was intraperitoneally administered to prevent MRONJ. The specimens were histopathologically and histomorphometrically evaluated. RESULTS Histomorphometrically, between the control and ZA groups, there was no statistically significant difference in total bone volume (P = .999), but there was a statistically significant difference in bone ratio in the extraction sockets (P < .001). A comparison of the bone ratio of the ZA group with the ZA/PTX group (PTX administered after extraction) showed no statistically significant difference (P = .69), but there was a statistically significant difference with the ZA/PTX/PTX group (PTX administered before and after extraction; P = .008). Histopathologically, between the control and ZA groups, there were statistically significant differences for inflammation (P = .013), vascularization (P = .022), hemorrhage (P = .025), and regeneration (P = .008). Between the ZA and ZA/PTX groups, there were no statistically significant differences for inflammation (P = .536), vascularization (P = .642), hemorrhage (P = .765), and regeneration (P = .127). Between the ZA and ZA/PTX/PTX groups, there were statistically significant differences for inflammation (P = .017), vascularization (P = .04), hemorrhage (P = .044), and regeneration (P = .04). CONCLUSION In this experimental model of MRONJ, it might be concluded that although PTX, given after tooth extraction, improves new bone formation that positively affects bone healing, it is not prophylactic. However, PTX given before tooth extraction is prophylactic. Therefore, PTX might affect healing in a positive way by optimizing the inflammatory response.
Collapse
Affiliation(s)
- Gül Merve Yalcin-Ulker
- Assistant Professor, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Okan University, Istanbul, Turkey.
| | - Alev Cumbul
- Assistant Professor, Department of Histology and Embryology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey
| | - Gonca Duygu-Capar
- Assistant Professor and Head of Department, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Trakya University, Edirne, Turkey
| | - Ünal Uslu
- Associated Professor and Head of Department, Department of Histology and Embryology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey
| | - Kemal Sencift
- Professor, Private Practice, Oral and Maxillofacial Surgery, Istanbul, Turkey
| |
Collapse
|
7
|
Makarov MV, Rybalkina EY, Anikina LV, Pukhov SA, Klochkov SG, Mischenko DV, Neganova ME, Khrustalev VN, Klemenkova ZS, Brel VK. 1,5-Diaryl-3-oxo-1,4-pentadienes based on (4-oxopiperidin-1-yl)(aryl)methyl phosphonate scaffold: synthesis and antitumor properties. Med Chem Res 2016. [DOI: 10.1007/s00044-016-1726-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
8
|
Abstract
Background:
Bisphosphonates are drugs commonly used for the medication and prevention of diseases caused by decreased mineral density. Despite such important medicinal use, they display a variety of physiologic activities, which make them promising anti-cancer, anti-protozoal, antibacterial and antiviral agents.
Objective:
To review physiological activity of bisphosphonates with special emphasis on their ongoing and potential applications in medicine and agriculture.
Method:
Critical review of recent literature data.
Results:
Comprehensive review of activities revealed by bisphosphonates.
Conclusion:
although bisphosphonates are mostly recognized by their profound effects on bone physiology their medicinal potential has not been fully evaluated yet. Literature data considering enzyme inhibition suggest possibilities of far more wide application of these compounds. These applications are, however, limited by their low bioavailability and therefore intensive search for new chemical entities overcoming this shortage are carried out.
Collapse
|
9
|
Kachbi Khelfallah S, Monteil M, Deschamp J, Gager O, Migianu-Griffoni E, Lecouvey M. Synthesis of novel polymerizable molecules bearing bisphosphonate. Org Biomol Chem 2015; 13:11382-92. [PMID: 26443553 DOI: 10.1039/c5ob01967b] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
In recent years, bisphosphonate chemistry has undergone an exponential growth due to the potential applications of these compounds in medicine and nanobiomaterial research. In this paper we describe the synthesis methods of different families of methacrylic monomers bearing a bisphosphonate with varying lengths of the chain, PEG linkers and more or less hydrolysable functions such as ester, carbamate or amide.
Collapse
Affiliation(s)
- S Kachbi Khelfallah
- Université Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, F-93017 Bobigny, France.
| | - M Monteil
- Université Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, F-93017 Bobigny, France.
| | - J Deschamp
- Université Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, F-93017 Bobigny, France.
| | - O Gager
- Université Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, F-93017 Bobigny, France.
| | - E Migianu-Griffoni
- Université Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, F-93017 Bobigny, France.
| | - M Lecouvey
- Université Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, F-93017 Bobigny, France.
| |
Collapse
|
10
|
Synthesis of new indole-based bisphosphonates and evaluation of their chelating ability in PE/CA-PJ15 cells. Eur J Med Chem 2015; 102:403-12. [PMID: 26301557 DOI: 10.1016/j.ejmech.2015.08.019] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Revised: 07/22/2015] [Accepted: 08/08/2015] [Indexed: 12/19/2022]
Abstract
Bisphosphonates are the most important class of antiresorptive agents used against osteoclast-mediated bone loss, and, more recently, in oncology. These compounds have high affinity for calcium ions (Ca(2+)) and therefore target bone mineral, where they appear to be internalized selectively by bone-resorbing osteoclasts and inhibit osteoclast function. They are extensively used in healthcare, however they are affected by severe side effects; pharmacological properties of bisphosphonates depend on their molecular structure, which is frequently the cause of poor intestinal adsorption and low distribution. In this work we synthesized six novel bisphosphonate compounds having a variably substituted indole moiety to evaluate their extra- and intracellular calcium chelating ability in PE/CA-PJ15 cells. Preliminary in silico and in vitro ADME studies were also performed and the results suggested that the indole moiety plays an important role in cell permeability and metabolism properties.
Collapse
|
11
|
Günaldi M, Afsar CU, Duman BB, Kara IO, Tatli U, Sahin B. Effect of the cumulative dose of zoledronic acid on the pathogenesis of osteonecrosis of the jaws. Oncol Lett 2015; 10:439-442. [PMID: 26171047 DOI: 10.3892/ol.2015.3156] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Accepted: 03/24/2015] [Indexed: 11/06/2022] Open
Abstract
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a severe bone disease for which the pathogenetic mechanisms and risk factors are not fully understood. The present study evaluated the data of 652 patients with bone metastasis that had undergone treatment with biphosphonates. Subsequently, 24 patients with BRONJ and 20 control patients without BRONJ that were treated with zoledronic acid were enrolled. It was found that BRONJ occurred in 3.6% of patients. The mean age and the administration of dental treatment were found to be significantly associated with BRONJ development (P=0.049 and P=0.013, respectively). The cumulative dose median in the BRONJ group was found to be significantly higher compared with the cumulative dose average in the control group (P=0.037). In addition, at the time of BRONJ development, improvement in the disease was determined to be better in the BRONJ group than in the control group (P=0.031). The present study determined that age, the existence of dental extraction and the cumulative dose of zoledronate were all important risk factors in BRONJ development.
Collapse
Affiliation(s)
- Meral Günaldi
- Department of Medical Oncology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey
| | - Cigdem Usul Afsar
- Department of Medical Oncology, Cukurova University Medical School, Adana, Adana, Turkey
| | - Berna Bozkurt Duman
- Department of Medical Oncology, Adana Research and Training Hospital, Adana, Adana, Turkey
| | - Ismail Oguz Kara
- Department of Medical Oncology, Cukurova University Medical School, Adana, Adana, Turkey
| | - Ufuk Tatli
- Faculty of Dentistry, Cukurova University, Adana, Adana, Turkey
| | - Berksoy Sahin
- Department of Medical Oncology, Cukurova University Medical School, Adana, Adana, Turkey
| |
Collapse
|
12
|
Puljula E, Turhanen P, Vepsäläinen J, Monteil M, Lecouvey M, Weisell J. Structural requirements for bisphosphonate binding on hydroxyapatite: NMR study of bisphosphonate partial esters. ACS Med Chem Lett 2015; 6:397-401. [PMID: 25893039 DOI: 10.1021/ml5004603] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2014] [Accepted: 02/21/2015] [Indexed: 11/29/2022] Open
Abstract
Eighteen different bisphosphonates, including four clinically used bisphosphonate acids and their phosphoesters, were studied to evaluate how the bisphosphonate structure affects binding to bone. Bisphosphonates with weak bone affinity, such as clodronate, could not bind to hydroxyapatite after the addition of one ester group. Medronate retained its ability to bind after the addition of one ester group, and hydroxy-bisphosphonates could bind even after the addition of two ester groups. Thus, several bisphosphonate esters are clearly bone binding compounds. The following conclusions about bisphosphonate binding emerge: (1) a hydroxyl group in the geminal carbon takes part in the binding process and increases the bisphosphonate's ability to bind to bone; (2) the bisphosphonate's ability to bind decreases when the amount of ester groups increases; and (3) the location of the ester groups affects the bisphosphonate's binding ability.
Collapse
Affiliation(s)
- Elina Puljula
- School of Pharmacy, University of Eastern Finland, Biocenter
Kuopio, PL-1627, 70210 Kuopio, Finland
| | - Petri Turhanen
- School of Pharmacy, University of Eastern Finland, Biocenter
Kuopio, PL-1627, 70210 Kuopio, Finland
| | - Jouko Vepsäläinen
- School of Pharmacy, University of Eastern Finland, Biocenter
Kuopio, PL-1627, 70210 Kuopio, Finland
| | - Maelle Monteil
- Université Paris 13, Sorbonne Paris Cité, CSPBAT, CNRS UMR 7244, 74, Rue Marcel Cachin, F-93017 Bobigny, France
| | - Marc Lecouvey
- Université Paris 13, Sorbonne Paris Cité, CSPBAT, CNRS UMR 7244, 74, Rue Marcel Cachin, F-93017 Bobigny, France
| | - Janne Weisell
- School of Pharmacy, University of Eastern Finland, Biocenter
Kuopio, PL-1627, 70210 Kuopio, Finland
| |
Collapse
|
13
|
Makarov MV, Rybalkina EY, Khrustalev VN, Röschenthaler GV. Modification of 3,5-bis(arylidene)-4-piperidone pharmacophore by phosphonate group using 1,2,3-triazole cycle as a linker for the synthesis of new cytostatics. Med Chem Res 2014. [DOI: 10.1007/s00044-014-1262-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
14
|
Monteil M, Migianu-Griffoni E, Sainte-Catherine O, Di Benedetto M, Lecouvey M. Bisphosphonate prodrugs: synthesis and biological evaluation in HuH7 hepatocarcinoma cells. Eur J Med Chem 2014; 77:56-64. [PMID: 24607589 DOI: 10.1016/j.ejmech.2014.02.054] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2013] [Revised: 02/19/2014] [Accepted: 02/21/2014] [Indexed: 12/25/2022]
Abstract
We investigated the biological effects of new synthesized bisphosphonates (BPs) on HuH7 hepatocarcinoma cells. BPs containing p-bromophenyl (R1 = p-Br, Ph, 2) in their side chain were the more potent to inhibit HuH7 cell viability. In addition, phenyl diesterified analogues (R2 = R3 = Ph, 2a) were more potent than methyl (R2 = R3 = Me, 2b) or non-esterified BPs (2) inducing more necrosis suggesting that they better entered into cells. Phosphodiesterase inhibitor (IBMX) reversed the effect of the esterified BPs and not that of non-esterified ones suggesting role of cell phosphodiesterases to release active BPs. BP analogues inhibited HuH7 cell migration but esterified ones had no effect on invasion due to the hiding of phosphonic groups. All together, these results indicated the therapeutic interest of these new BP prodrugs.
Collapse
Affiliation(s)
- Maelle Monteil
- Université Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, 74, Rue Marcel Cachin, F-93017 Bobigny, France
| | - Evelyne Migianu-Griffoni
- Université Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, 74, Rue Marcel Cachin, F-93017 Bobigny, France
| | - Odile Sainte-Catherine
- Université Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, 74, Rue Marcel Cachin, F-93017 Bobigny, France
| | - Mélanie Di Benedetto
- Université Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, 74, Rue Marcel Cachin, F-93017 Bobigny, France
| | - Marc Lecouvey
- Université Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, 74, Rue Marcel Cachin, F-93017 Bobigny, France.
| |
Collapse
|
15
|
Migianu-Griffoni E, Chebbi I, Kachbi S, Monteil M, Sainte-Catherine O, Chaubet F, Oudar O, Lecouvey M. Synthesis and Biological Evaluation of New Bisphosphonate–Dextran Conjugates Targeting Breast Primary Tumor. Bioconjug Chem 2014; 25:224-30. [DOI: 10.1021/bc400317h] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Evelyne Migianu-Griffoni
- Université Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d’Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, 74, Rue Marcel Cachin F-93017 Bobigny, France
| | - Imène Chebbi
- Université Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d’Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, 74, Rue Marcel Cachin F-93017 Bobigny, France
| | - Souad Kachbi
- Université Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d’Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, 74, Rue Marcel Cachin F-93017 Bobigny, France
| | - Maelle Monteil
- Université Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d’Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, 74, Rue Marcel Cachin F-93017 Bobigny, France
| | - Odile Sainte-Catherine
- Université Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d’Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, 74, Rue Marcel Cachin F-93017 Bobigny, France
| | - Frédéric Chaubet
- Université Paris 13, Sorbonne Paris Cité, Laboratoire BPC, INSERM U 698, 99, Avenue Jean-Baptiste
Clément F-93430 Villetaneuse, France
| | - Olivier Oudar
- Université Paris 13, Sorbonne Paris Cité, Laboratoire BPC, INSERM U 698, 99, Avenue Jean-Baptiste
Clément F-93430 Villetaneuse, France
| | - Marc Lecouvey
- Université Paris 13, Sorbonne Paris Cité, Laboratoire de Chimie, Structure, Propriétés de Biomatériaux et d’Agents Thérapeutiques (CSPBAT), CNRS UMR 7244, 74, Rue Marcel Cachin F-93017 Bobigny, France
| |
Collapse
|
16
|
A Retrospective Study Evaluating Frequency and Risk Factors of Osteonecrosis of the Jaw in 576 Cancer Patients Receiving Intravenous Bisphosphonates. Am J Clin Oncol 2012; 35:386-92. [DOI: 10.1097/coc.0b013e3182155fcb] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Chebbi I, Migianu-Griffoni E, Sainte-Catherine O, Lecouvey M, Seksek O. In vitro assessment of liposomal neridronate on MDA-MB-231 human breast cancer cells. Int J Pharm 2009; 383:116-22. [PMID: 19748562 DOI: 10.1016/j.ijpharm.2009.09.011] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2009] [Revised: 09/04/2009] [Accepted: 09/07/2009] [Indexed: 11/28/2022]
Abstract
Bisphosphonates have been used for decades in the standard therapy of bone-related diseases, including bone metastasis of various malignancies, and they might as well be toxic on early cancer cells themselves. In order to allow a better delivery of neridronate (a N-containing bisphosphonate with relatively poor activity), liposomes were evaluated in vitro on cancer cell lines (MDA-MB-231, U87-MG and Caco2). After chemical synthesis, this water-soluble molecule was encapsulated into liposomes containing DOPC:DOPG:Chol (72:27:1 molar ratio). The influence of neridronate (free or liposomal) on cell viability or proliferation after treatment was evaluated using the MTT method, as well as cell migration and invasion assays; these techniques showed a drastic improvement of the action of neridronate on MDA-MB-231 cells with an EC(50) 50 times lower when neridronate was encapsulated. Internalization of liposomes was followed by flow cytometry and fluorescence microscopy, demonstrating internalization via the endocytic pathway. Furthermore, since overexpression of matrix metalloproteinases (particularly MMP-2 and MMP-9) has been correlated to poor prognosis in many cancer types, detection of MMP expression is a satisfactory indication of the therapy efficiency and was then performed on treated cells. On MDA-MB-231 cells, MPPs expression was also significantly reduced by neridronate while entrapped in liposomes.
Collapse
Affiliation(s)
- Imène Chebbi
- ANBioPhy, CNRS FRE 3207, Université Pierre & Marie Curie, Génopole Campus 1, Evry, France
| | | | | | | | | |
Collapse
|
18
|
Guénin E, Lecouvey M, Hardouin J. Study of bisphosphonates by matrix-assisted laser desorption/ionization mass spectrometry--influence of alkali atoms on fragmentation patterns. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2009; 23:1234-1240. [PMID: 19306287 DOI: 10.1002/rcm.3984] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
1-hydroxymethylene-1,1-bisphosphonic acids (or bisphosphonates) are compounds that have interesting pharmacological applications. However, few mass spectrometric investigations have been carried out to determine their fragmentation patterns. Herein, we evaluated different matrices for the study by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOFMS) of the formation and fragmentation of the protonated, the cationized (MNa+ and MK+) and the deprotonated bisphosphonates. Some in-source fragmentations were observed both in positive and in negative ion modes. The fragmentation patterns obtained in post-source decay mode are also discussed. In contrast to previous electrospray ionization/multi-stage mass spectrometry (ESI-MSn) studies, some new fragmentation pathways were deduced and the effects of alkali ions on the fragmentation patterns were shown. The results summarized here completed the data previously recorded by ESI-MSn and could be used for the characterization of bisphosphonates as alkali complexes in biological mixtures.
Collapse
Affiliation(s)
- Erwann Guénin
- Equipe Chimie Bioorganique et Bionanomatériaux (C2B), Laboratoire de Chimie, Structures, Propriétés de Biomatériaux et d'Agents Thérapeutiques (CSPBAT), Université Paris 13, 74 rue Marcel Cachin, 93017 Bobigny cedex, France
| | | | | |
Collapse
|
19
|
Abdelkarim M, Guenin E, Sainte-Catherine O, Vintonenko N, Peyri N, Perret GY, Crepin M, Khatib AM, Lecouvey M, Di Benedetto M. New symmetrically esterified m-bromobenzyl non-aminobisphosphonates inhibited breast cancer growth and metastases. PLoS One 2009; 4:e4685. [PMID: 19262688 PMCID: PMC2650402 DOI: 10.1371/journal.pone.0004685] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2008] [Accepted: 02/02/2009] [Indexed: 01/17/2023] Open
Abstract
BACKGROUND Although there was growing evidence in the potential use of Bisphosphonates (BPs) in cancer therapy, their strong osseous affinities that contrast their poor soft tissue uptake limited their use. Here, we developed a new strategy to overcome BPs hydrophilicity by masking the phosphonic acid through organic protecting groups and introducing hydrophobic functions in the side chain. METHODOLOGY/PRINCIPAL FINDINGS We synthesized non-nitrogen BPs (non N-BPs) containing bromobenzyl group (BP7033Br) in their side chain that were symmetrically esterified with hydrophobic 4-methoxphenyl (BP7033BrALK) and assessed their effects on breast cancer estrogen-responsive cells (T47D, MCF-7) as well as on non responsive ones (SKBR3, MDA-MB-231 and its highly metastatic derived D3H2LN subclone). BP7033Br ALK was more efficient in inhibiting tumor cell proliferation, migration and survival when compared to BP7033Br. Although both compounds inhibited tumor growth without side effects, only BP7033Br ALK abrogated tumor angiogenesis and D3H2LN cells-induced metastases formation. CONCLUSION/SIGNIFICANCE Taken together these data suggest the potential therapeutic use of this new class of esterified Bisphosphonates (BPs) in the treatment of tumor progression and metastasis without toxic adverse effects.
Collapse
Affiliation(s)
- Mohamed Abdelkarim
- Université Paris 13, CNRS FRE CSPBAT, Laboratoire de Chimie Structurale Biomoléculaire, Laboratoire de pharmacologie, Université Paris 13, UFR SMBH, Bobigny, France
- INSERM 553 Endothélium et Angiogénèse Laboratoire d'Hémostase, Paris, France
| | - Erwann Guenin
- Université Paris 13, CNRS FRE CSPBAT, Laboratoire de Chimie Structurale Biomoléculaire, Laboratoire de pharmacologie, Université Paris 13, UFR SMBH, Bobigny, France
| | - Odile Sainte-Catherine
- Université Paris 13, CNRS FRE CSPBAT, Laboratoire de Chimie Structurale Biomoléculaire, Laboratoire de pharmacologie, Université Paris 13, UFR SMBH, Bobigny, France
| | - Nadejda Vintonenko
- Université Paris 13, CNRS FRE CSPBAT, Laboratoire de Chimie Structurale Biomoléculaire, Laboratoire de pharmacologie, Université Paris 13, UFR SMBH, Bobigny, France
- INSERM 553 Endothélium et Angiogénèse Laboratoire d'Hémostase, Paris, France
| | - Nicole Peyri
- INSERM 553 Endothélium et Angiogénèse Laboratoire d'Hémostase, Paris, France
| | - Gerard Yves Perret
- Université Paris 13, CNRS FRE CSPBAT, Laboratoire de Chimie Structurale Biomoléculaire, Laboratoire de pharmacologie, Université Paris 13, UFR SMBH, Bobigny, France
| | - Michel Crepin
- INSERM 553 Endothélium et Angiogénèse Laboratoire d'Hémostase, Paris, France
| | | | - Marc Lecouvey
- Université Paris 13, CNRS FRE CSPBAT, Laboratoire de Chimie Structurale Biomoléculaire, Laboratoire de pharmacologie, Université Paris 13, UFR SMBH, Bobigny, France
| | - Mélanie Di Benedetto
- Université Paris 13, CNRS FRE CSPBAT, Laboratoire de Chimie Structurale Biomoléculaire, Laboratoire de pharmacologie, Université Paris 13, UFR SMBH, Bobigny, France
- INSERM/UP7 UMRS 940. Equipe Avenir, IGM, Paris, France
- * E-mail:
| |
Collapse
|
20
|
Fehm T, Beck V, Banys M, Lipp H, Hairass M, Reinert S, Solomayer E, Wallwiener D, Krimmel M. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 2009; 112:605-9. [DOI: 10.1016/j.ygyno.2008.11.029] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2008] [Revised: 11/13/2008] [Accepted: 11/14/2008] [Indexed: 10/21/2022]
|